More Evidence Supporting the Clinical Benefit of Niraparib Maintenance Therapy After Chemo in Advanced Ovarian Cancer

March 31, 2020 12:00 pm

By Susan Moench, PhD, PA-C

Preliminary assessments of secondary study endpoints of a phase 3 clinical trial evaluating maintenance therapy with niraparib, an inhibitor of poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP), compared with placebo in patients with newly diagnosed advanced ovarian … Read more